Sanofi obtained approval from the European Commission to market its injectable drug Lemtrada, or alemtuzumab, for treatment of multiple sclerosis. Lemtrada will join Sanofi's other MS drug, Aubagio, which was cleared in Europe in the past month. Sanofi plans to begin selling both treatments in the European Union soon.

Full Story:

Related Summaries